866928-31-6

Basic information

• Product Name: 1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidin-4-ol
• CAS NO: 866928-31-6
• Molecular Weight: 500.948
• Mol File: 866928-31-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidin-4-ol(866928-31-6)
• EPA Substance Registry System: 1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-trifluoromethyl-piperidin-4-ol(866928-31-6)

Safety Data

• Hazardous Substances Data: 866928-31-6(Hazardous Substances Data)

Upstream product

• 690264-31-4 5-(4-chloro-phenyl)-2-ethynyl-pyridine 
• 690265-96-4 methanesulfonic acid-2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy} ethyl ester 
• 373603-69-1 4-trifluoromethyl-4-hydroxypiperidine 
• 690265-95-3 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethanol 
• 540-38-5 p-Iodophenol 
• 29639-77-8 2-(4-iodophenoxy)ethanol 
• 111770-80-0 3-bromo-6-(trimethylsilylethynyl)pyridine 
• 690264-30-3 5-(4-chloro-phenyl)-2-trimethylsilanylethynyl-pyridine 

Relevant articles and documents

Design, synthesis and evaluation of MCH receptor 1 antagonists - Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414

Abstract Despite recent approvals of anti-obesity drugs there is still a high therapeutic need for alternative options with higher efficacy in humans. As part of our MCH-R1 antagonist program for the treatment of obesity, a series of biphenylacetamide HTS

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to individual alkyne compounds with an antagonistic action against the MCH-receptor. Said compounds are suitable for producing medicaments for the treatment of metabolic disorders and/or eating disorders, in particular adiposity and diabetes.